Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cirrhotic cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impaired cerebral microcirculation induced by ammonium chloride in rats is due to cortical adenosine release

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Hepatic and cardiac hemodynamics and systemic inflammation in cirrhosis: It takes three to tango

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Micro-elimination - A path to global elimination of hepatitis C

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Torque-Teno virus viral load as a potential endogenous marker of immune function in solid organ transplantation

    Research output: Contribution to journalReviewResearchpeer-review

  2. Prognostic molecular markers in pediatric liver disease - Are there any?

    Research output: Contribution to journalReviewResearchpeer-review

  • Espen Melum
  • Styrbjörn Friman
  • Kristian Bjøro
  • Allan Rasmussen
  • Helena Isoniemi
  • Henrik Gjertsen
  • Lars Bäckman
  • Antti Oksanen
  • Michael Olausson
  • Frans F Duraj
  • Bo-Göran Ericzon
View graph of relations

BACKGROUND/AIMS: Liver transplantation (LTX) is the only curative treatment for end-stage liver disease caused by hepatitis C (HCV). Hepatocellular carcinoma (HCC) is common in patients with HCV cirrhosis.

METHODS: Two hundred and eighty-two HCV patients listed for LTX in the Nordic countries in a 17-year period were included. For comparison a group of patients with non-viral chronic liver disease (n=1552) was used.

RESULTS: Two hundred and fifty-three (90%) patients received a first liver allograft. HCC was found in 38% of the explanted livers. Survival at 1, 3 and 5years was 82%, 69% and 61% vs. 85%, 80% and 76% for the comparison group (p<0.0001), this survival difference was also evident when excluding patients with HCC (p=0.007). HCV patients with HCC had 1, 3 and 5year survival of 73%, 52% and 46% compared with 88%, 80% and 71% for the HCV patients without HCC (p=0.0005). In an intention-to-treat analysis (from time of acceptance to the waiting list) HCV was also associated with an impaired survival.

CONCLUSIONS: HCV cirrhosis, which is now also an important indication for LTX in the Nordic countries, and significantly impairs survival following LTX. Concomitant HCC and donor age are the two most important factors contributing to an impaired survival.

Original languageEnglish
JournalJournal of Hepatology
Volume47
Issue number6
Pages (from-to)777-83
Number of pages7
ISSN0168-8278
DOIs
Publication statusPublished - Dec 2007

    Research areas

  • Adult, Carcinoma, Hepatocellular, Case-Control Studies, Comorbidity, Female, Hepatitis C, Humans, Liver Cirrhosis, Liver Transplantation, Male, Middle Aged, Scandinavian and Nordic Countries, Survival Rate

ID: 44955351